R&d results

At present, the company's core products include D-shant® atrial shunt for heart failure treatment, D-shufo™ patent ovale occluder for cardiogenic stroke prevention, DOCS VALVE® transcatheter aortic valve replacement system for valvular disease treatment and other innovative devices; Supporting interventional consumable products heart occluder delivery system, atrial septal puncture system, integrated occluder interventional delivery system, left ventricular guide wire, etc.

Pre-developed products include active heart failure monitoring devices, transcatheter mitral valve replacement systems, ventricular assist devices and other innovative products.

In the next few years, the company plans to target major clinical demand products in the professional field of structural cardiology, reserve 1-2 emerging technologies every year, and launch a project in the first echelon of domestic projects every 1-2 years. The products cover the frontier of minimally invasive treatment of heart failure and structural heart disease.